Cannabidiol contraindications
Pro Research Analysisby 
Searched over 200M research papers for "cannabidiol contraindications"
Cannabidiol Contraindications: A Comprehensive Overview
Introduction to Cannabidiol (CBD) and Its Uses
Cannabidiol (CBD) is a non-intoxicating cannabinoid derived from the Cannabis sativa plant. It has gained significant attention for its potential therapeutic benefits, particularly in treating conditions such as epilepsy, anxiety, and chronic pain1 4. Despite its growing popularity, it is crucial to understand the contraindications and adverse effects associated with CBD use.
Adverse Effects and Toxicity of CBD
General Adverse Effects
CBD is not without risks. Studies have reported various adverse effects (AEs) in both animal and human models. In animals, high doses of CBD have been linked to developmental toxicity, embryo-fetal mortality, central nervous system inhibition, neurotoxicity, hepatocellular injuries, and reproductive system alterations1. In humans, common AEs include diarrhea, fatigue, vomiting, and somnolence1 2.
Serious Adverse Events
Clinical trials have highlighted several serious adverse events (SAEs) associated with CBD use. These include abnormal liver function tests, pneumonia, and increased likelihood of withdrawal due to adverse events2. Specifically, in studies involving childhood epilepsy, CBD was associated with significant interactions with other medications, such as clobazam and sodium valproate, leading to increased SAEs2.
Drug-Drug Interactions
Hepatic Abnormalities
CBD can cause hepatic abnormalities, particularly when used in conjunction with other medications. This is especially relevant in the treatment of epilepsy, where CBD is often used alongside other antiepileptic drugs1 2. Monitoring liver function is essential when prescribing CBD, especially at higher doses.
Interaction with Psychiatric Medications
In the context of psychiatric disorders, CBD has shown potential benefits but also poses risks. The most frequently reported AEs in psychiatric studies are sedation and dizziness3. Given the limited evidence and the potential for drug-drug interactions, further research is needed to establish the safety profile of CBD in psychiatric settings3.
Specific Contraindications
Epilepsy and Seizure Disorders
While CBD has proven efficacy in reducing seizure frequency in conditions like Lennox-Gastaut syndrome and Dravet syndrome, it also comes with a higher rate of AEs compared to placebo. These include somnolence, decreased appetite, diarrhea, and increased serum aminotransferases5. Therefore, careful consideration and monitoring are required when using CBD as an adjunctive treatment for epilepsy.
Use in Children
The use of CBD in children, particularly for epilepsy, has shown both benefits and risks. The interaction with other medications and the potential for serious adverse events like pneumonia and abnormal liver function tests necessitate cautious use and close monitoring2 5.
Conclusion
While CBD offers promising therapeutic benefits for various conditions, it is not without risks. Adverse effects, drug-drug interactions, and specific contraindications must be carefully considered by clinicians. Further research is essential to fully understand the safety profile of CBD, especially in populations with complex medical needs. Clinicians should exercise caution and ensure thorough monitoring when recommending CBD, particularly for off-label uses.
Sources and full results
Most relevant research papers on this topic
Cannabidiol Adverse Effects and Toxicity
CBD has proven therapeutic efficacy for serious conditions like Dravet and Lennox-Gastaut syndromes, but its use should be based on a careful consideration of adverse effects and potential drug-drug interactions.
Systematic Review
Rigorous Journal
Highly CitedAdverse effects of cannabidiol: a systematic review and meta-analysis of randomized clinical trials
CBD is well-tolerated and has few serious adverse effects, but interactions with other medications should be monitored.
Meta-Analysis
Very Rigorous JournalHighly CitedIs there a role for cannabidiol in psychiatry?
CBD's efficacy and safety in psychiatry are still inconclusive, with limited evidence for major depressive and bipolar disorders, and limited evidence for cannabis withdrawal and addiction.
Systematic ReviewClinicians' Guide to Cannabidiol and Hemp Oils.
Cannabidiol (CBD) oils show promise for treating various conditions, particularly pain, but careful selection and regulation are crucial for safe and effective patient care.
Systematic ReviewHighly CitedEfficacy and Safety of Cannabidiol in Epilepsy: A Systematic Review and Meta-Analysis
CBD is an effective and safe adjunctive treatment for patients with epilepsy, reducing seizure frequency by at least 50% without causing significant withdrawal or adverse events.
Meta-AnalysisHighly CitedCannabidiol in Humans—The Quest for Therapeutic Targets
High-dose oral CBD may have therapeutic effects for social anxiety disorder, insomnia, and epilepsy, but may cause mental sedation.
Systematic ReviewHighly CitedA Systematic Review on the Pharmacokinetics of Cannabidiol in Humans
Cannabidiol's pharmacokinetics in humans are insufficiently studied, with discrepancies in bioavailability and half-life, highlighting the need for robust data from various formulations for future therapeutic success.
Systematic ReviewHighly CitedCannabidiol for the Reduction of Cue-Induced Craving and Anxiety in Drug-Abstinent Individuals With Heroin Use Disorder: A Double-Blind Randomized Placebo-Controlled Trial.
CBD shows potential in reducing cue-induced craving and anxiety in drug-abstinent individuals with heroin use disorder, suggesting it could be a potential treatment option for opioid use disorder.
RCTHighly CitedCannabidiol drug interaction considerations for prescribers and pharmacists
Cannabidiol drug interactions are likely to occur at certain doses, and clinicians should be aware of these interactions and monitor patients for potential drug interactions.
Systematic ReviewOral cannabidiol does not produce a signal for abuse liability in frequent marijuana smokers.
Oral cannabidiol does not show any signals of abuse liability at the doses tested in frequent marijuana smokers, potentially informing regulatory decisions regarding its Schedule I status on the CSA.
RCTHighly Cited